전체메뉴 닫기
Запись на приём
Расписание врачей
Запись на приём
Отделения
Найти отделения и специализированные центры

Лист специализированных центров

Отделения

Найти отделения и медицинских персоналов

Сооружения и услуги
Первый визит в больницу
Амбулаторный приём · скорая помощь · госпитализация

Процесс амбулаторный приём

Процесс скорой помощи

Процесс госпитализации/выписки

Расположение и направления
Удобства

B1

1F

2F

3F

Контактная информация
Как найти нас

Карта/ Информация об использовании автомобиля

Информация об использовании общественного транспорта

ЧаВо
Центр послеродового ухода
Медицинская информация
Рубрика о здоровом образе жизни
ЧА СМИ
Здоровая беременность с нуля до конца

We always promise
the best care

Центр гинекологической онкологии Prof. Noh, Ju Won

Расписание Пн Вт Ср Чт Пт Сб
До обеда
После обеда

Специализация

Гинекологический рак, Перитонеальный рак, Гинекологические доброкачественные заболевания(доброкачественная опухоль, эндометриоз, аденомиоз матки), Гинекологическая эндоскопическая операция(роботизированная операция, лапароскопическая операция, гистероскопическая операция), Операция по сокращению аденомиоза

Карьеры профессора

  • Seoul National University
  • Dongguk University
  • CHA University

Медицинский опыт

  • MD Anderson Cancer Center
  • National cancer center
  • Director, OBGY, Dongguk Ilsan hospital
  • OBGY, CHA Ilsan medical center, CHA University
  • Gynecologic oncology center, CHA Ilsan medical center, CHA University

Награды

  • Training, Gynecologic oncology, Friedrich-Schiller University, German
  • Training, Gynecologic oncology, Leipzig University, German
  • Novartis Merit award, in the 41th The Korean Cancer Association
  • GSK Award for excellent research, in the 39th The Korean Cancer Association conference
  • Merit Award, in the 10th International Conference of ACOS(2012)

  • Научная статья
  1. Safety and effective of dienogest (Visanne®) for treatment of endometriosis: a large prospective cohort study. Reprod Sci (in publication)
  2. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther 2019;20:1-10. doi: 10.1080/15384047
  3. Type-specific viral load and physical state of HPV type 16, 18, and 58 as diagnostic biomarkers for high-grade squamous intraepithelial lesions or cervical cancer. Cancer Res Treat 2019; (In publication)
  4. Practice guidelines for management of ovarian cancer in Korea: A Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol 2018;29(4):e56
  5. Surg Endosc 2018;32:2643-2649
  6. Surgical manual of the Korean Gynecologic Oncology Group: Classification of hysterectomy and lymphadenectomy. J Gynecol Oncol 2017;28(1):e5.
  7. Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. J Gynecol Oncol, 2015;26(2) :90-99.
  8. Factors Affecting Unused Remaining Volume of Intravenous Patient-controlled Analgesia in Patients Following Laparoscopic Gynecologic Surgery. Asian Nursing Research 2014 Dec8:300-4.
  9. Biological effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clin Cancer Res 2014;May 15;20(10): 2740-50.
  10. Crosstalk between EphA2 and Braf/Craf is a key determinant of response to Dasatinib. Clin Cancer Res 2014 Apr:;20(7):1846-55.
  11. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 2014;Jan;132(1)166-75.
  12. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia .2013May;15(5):502-10.
  13. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 2013 Feb;128(2); 344-8.
  14. Clinical and biological relevance of enhancer of zeste homolog 2 in triple negative breast cancer. Human Pathol 2012;43(10):1638-44.
  15. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer 2012;22:1570-1576.
  16. A novel platform for detection of CK+ and CK- CTCs. Cancer Discovery 2011;1(7):580-586.
  17. Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res.2011;71:6030-6039.
  18. Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res. 2011; 17 (16):5367-78.
  19. A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrhea. Complement Ther Med 2011Aug;19(4):187-93
  20. Diastolic forward flow in the fetal main pulmonary artery and its implication for fetal cardiac cycle evaluation. J Perinat Med 2011.2011;39:445-450.
  21. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 2011;21(4):668-672.
  22. Chitosan hydrogel for localized gene silencing. CancerBiolTher2011;11:839-845.
  23. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011 Apr;13(4):309-19.
  24. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res . 2011 Apr 1:17(7):1713-1721.
  25. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res 2010;16(15):3910-22.
  26. p53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res 2010;18(9):453-9.
  27. EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. Clin Cancer Res; 2010;16(9) May: 2562–70.
  28. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009 Oct20; 27(30): 5088-93.
  29. Successful twin pregnancy after vaginal radical trachelectomy using transabdominal cervicoisthmic cerclage. Am J Obstet Gynecol 2007;197(3):e5-6.
  30. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci 2007;98:329-333.
  31. Validation study of the Korean version of the M.D. Anderson Symptom Inventory. J Pain Symptom Manag.2006;Apr;31(4):345-52.
  32. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 2006;132(5):302-8.
  33. Comparison of accuracies of MRI and PET/CT in presurgical detection of lymph node metastases in patients with uterine cervical cancer: a prospective study. Cancer2006;106(4):914-22.
  34. Single nucleotide polymorphism: a new risk factor for endometrial cancer? Future Oncol 2005;1(3):323-30.
  35. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. Eur J Cancer 2005;41(14):2086-92.
  36. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol I 2005;32:757-763.
  37. Pretreatment laparoscopic surgical staging in locally advanced cervical cancer: Preliminary results in Korea. Gynecol Oncol 2005;97(2):468-475.
  38. Validation Study of the Korean Version of the Bried Fatigue Inventory. J Pain Symptom Manag 2005;29:165-172.
  39. Prevalence and Determinants of Genital Infection with Papillomavirus, in Female and Male University. J Infect Dis 2004;190:468-76.
  40. p53 and p21 genetic polymorphism and susceptibility to endometrial cancer. Gynecol Oncol 2004;93:499-505.
  41. Genetic polymorphism of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 2004;93:14-18.
  42. Interferon, alpha 17 (IFNA17) Ile 184Arg polymorphism and cervical cancer risk. Cancer Lett 2003;189:183-8.
  43. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002;184:57-63.
  44. A comparison of the therapeutic efficacies of large loop excision of the transformation zone (LLETZ) and hysterectomy for the treatment of cervical intraepithelial neoplasia (CIN) III. Int J Gynecol Cancer 2001;11:387-391.
  45. Polymorphism in Codon 31 of p21 and Cervical Cancer Susceptibility in Korean women. Cancer Lett 2001;165:59-62.
  46. Polymorphism of p53 codon 72 and the risk of cervical cancer in Korean women. Am J Obstet Gynecol 2001;184:55-8.